CN104861057A - Recombinant human kininogenase and application thereof - Google Patents
Recombinant human kininogenase and application thereof Download PDFInfo
- Publication number
- CN104861057A CN104861057A CN201510159607.9A CN201510159607A CN104861057A CN 104861057 A CN104861057 A CN 104861057A CN 201510159607 A CN201510159607 A CN 201510159607A CN 104861057 A CN104861057 A CN 104861057A
- Authority
- CN
- China
- Prior art keywords
- kallidinogenase
- recombinant human
- high molecular
- sepharose
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
The invention relates to high-molecular-weight recombinant human kininogenase, and a preparation method and application thereof. Specifically, the invention relates to the high-molecular-weight recombinant human kininogenase prepared by using a mammal cell culture production method and specific purifying technology for the first time. According to results of SDS-PAGE electrophoresis determination, the molecular weight of the high-molecular-weight recombinant human kininogenase is 43 to 49 KDa; the high-molecular-weight recombinant human kininogenase is glycoprotein and contains three N-Link glycosylation binding sites which are respectively located at Asn78, Asn84 and Asn141; and compared with kininogenase originated from human urine, the high-molecular-weight recombinant human kininogenase has a more complicated and more complete glycosylation level and obviously reduces a deamidation level. The high-molecular-weight recombinant human kininogenase obtained in the invention can substantially prolong in-vivo half-life and reduce side effects. The invention also relates to application of the high-molecular-weight recombinant human kininogenase in treatment of kidney failure.
Description
Technical field
The present invention relates to a kind of recombinant human kallidinogenase, its preparation method and application.More specifically, the present invention relates to and utilize molecular biology and host cell production method to prepare recombinant protein, and obtain high molecular recombinant human kallidinogenase first by specific purifying process.The high molecular recombinant human kallidinogenase energy significant prolongation Half-life in vivo that the present invention obtains and minimizing side effect, the invention still further relates to the applied research of recombinant human kallidinogenase in treatment renal failure.
Background technology
People's kallidinogenase (Kininogenase) is a kind of containing 238 amino acid whose glycoprotein, it can make prokinin be degraded into kassinin kinin, kassinin kinin special receptor on target organ is combined and can produces a series of biological effect, as vasodilation increases volume of blood flow, improves sanguimotor effect.
China's approval people of having gone on the market only is had at present to urinate the kallidinogenase product in source in the world, as everyone knows, the product extracted from people's urine has potential virus contamination and the defect such as the quality of production is uncontrollable, waits the general not receiver of developed country to urinate derived products to go on the market American-European-Japanese.Japanese enterprises is separation and Extraction kallidinogenase for the clinical study of people from people's urine the earliest, but people's UK drug side effect is large, and particularly blood pressure drops is obvious, and therefore Japan finally could not go on the market Approved by UK.
Comparatively speaking, recombinant protein is in its purity, antigenicity, security, have the incomparable advantage of urine product-derived without in self urine borne virus infection etc., show wide medical prospect, but at home and abroad there is no the listing of recombinant human kallidinogenase medicine so far.
Obtain recombinant human kallidinogenase by gene recombination technology and become better selection, and the recombinant glycoprotein with activity in vivo will be prepared, existing prokaryotic cell prokaryocyte (as intestinal bacteria) and yeast expression system all cannot realize, in mammalian host cell, only express recombinant protein could realize more complete glycosylation, in fact, degree of glycosylation and the function such as albumen activity in vivo and transformation period of albumen are closely related, and recombinant protein level of glycosylation depends on again cell culture condition and purifying process.
On the other hand, the special purification process step (60 DEG C thermostatically heating 10 hours) that existing urine people from source kallidinogenase and recombinant human kallidinogenase all adopt due to it easily causes its protein deamidation degree higher, albumen is easily hydrolysis, isomerization further in vivo, thus affect the stability of albumen entirety and produce side reaction, be exaggerated the shortcomings such as the short and side effect of its transformation period is large further; Based on removing the considerations such as potential virus contamination risk, urine people from source kallidinogenase gone on the market and recombinant human kallidinogenase all have employed the method for 60 DEG C of thermostatically heating heat inactivation virus of 10 hours, this processing method causes albumen deacylated tRNA amine reaction meeting quite violent, and this point has also been confirmed in our experiment, people's kallidinogenase deacylated tRNA amine in commercially available urine source has been on close level 50%.The l-asparagine site desamidization of N sugar chain is caused by originate people's kallidinogenase or recombinant human kallidinogenase of the urine of produced in conventional processes, affect purity of protein and stability, for this albumen with complicated sugar chain of people's kallidinogenase, there are potential risks, therefore, there is the shortcomings such as transformation period short and side effect is large in existing urine people from source kallidinogenase or recombinant human kallidinogenase.The defect of method of going out based on high temperature (60 DEG C thermostatically heating 10 hours) heating, modern main technology removes virus to adopting the gentle methods such as deep layer membrane filtrations containing multiple sugar chain protein purification.Many documents that early stage has delivered have confirmed that multiple sugar chain protein deamidation and temperature and PH have substantial connection, temperature is all demonstrated higher in the bioengineering field such as recombinant human vascular endothelial inhibin and antibody early-stage Study, desamidation is more obvious, the antibody drug of current listing using deacylated tRNA amine level as an important quality control standard because it is significant to the aspect such as security, side effect that product is potential.
There is report recombinant human kallidinogenase close with people's UK molecular weight, the research report of the high molecular recombinant human kallidinogenase that at home and abroad there is no so far.
Summary of the invention
The present invention aims to provide a kind of high molecular recombinant human kallidinogenase, preparation method and application thereof, and its deacylated tRNA amine level of this recombinant human kallidinogenase, less than 10%, significantly reduces side effect and extends the transformation period.Preferably, the invention provides high molecular recombinant human kallidinogenase, the preparation method that a kind of SDS-PAGE cataphoretic determination molecular weight is 43-49KD and treating the application in renal failure.High molecular recombinant human kallidinogenase energy significant prolongation Half-life in vivo of the present invention and the hypotensive side effect of minimizing.
An object of the present invention is to provide a kind of high molecular recombinant human kallidinogenase.This recombinant human kallidinogenase forms a strand (see sequence 1) by 238 amino-acid residues, and N-end and C-terminal amino acid residue are respectively Isoleucine and Serine, and by SDS-PAGE cataphoretic determination, its molecular weight is 43-49KDa.This recombinant human kallidinogenase is a kind of glycoprotein, containing 3 N-Link glycosylation binding sites, lays respectively at Asn78, Asn84 and Asn141.Containing 5 pairs of S-S keys in this recombinant human kallidinogenase molecule, be respectively Cys7-Cys150, Cys26-Cys42, Cys129-Cys196, Cysl61-Cys175 and Cys186-Cys211, iso-electric point is about 4.0.
Another object of the present invention is to provide a kind of preparation method of high molecular recombinant human kallidinogenase.This preparation method comprises:
1. build the expression vector of encoding recombinant human's kallidinogenase:
Artificial synthesis is adopted to obtain leading peptide and the mature protein gene (sequence No.1) of encoding human kallidinogenase, the expression vector (as pCMV-DHFR) being inserted into mammalian cell expression vector (as pCMV/ZEO) or improving, obtains containing people's kallidinogenase destination gene expression carrier pCMV-people kallidinogenase-DHFR;
2. the stably express of recombinant human kallidinogenase in mammalian host cell:
Expression vector containing people's vascular relaxation fibroin is transfected into mammalian host cell, the cell strain of screening stably express target protein;
3. concentration cultivation Restruction people kallidinogenase:
The above-mentioned stable cell line screened is proceeded to cell response tank and carries out large scale culturing, when cell density reaches 1 × 10
7individual/mL time, temperature is down to 33 DEG C by 37 DEG C, at such a temperature cultivate until express output no longer increase;
4. the purifying of high molecular recombinant human kallidinogenase:
(1) pre-treatment before upper chromatography column: the above-mentioned nutrient solution containing recombinant human kallidinogenase is carried out centrifugal segregation cell debris, collecting cell supernatant liquor regulates pH and centrifugal segregation precipitation.
(2) anion exchange chromatography: with same anion chromatography post, use the Tris-HCl damping fluid of different N aCl concentration, 0.2-0.4M NaCl prick post, 0.05-0.15M NaCl hanging column, successively make recombinant human vascular relaxation fibroin prick post and hanging column, described anion-exchange column comprises: Q Sepharose H.P, Q Sepharose F.F, Q Sepharose 4F.F, Q Sepharose XL, QAE Sephadex A-25, QAE Sephadex A-50, STREAMLINE Q XL.Preferably, QAE Sephadex A-25, QAE Sephadex A-50.
(3) affinity column stepwise elution: adopt affinity column (Benzamidine Sepharose 4Fast Flow, GE) purifying, by the elution requirement of different salt concn, under 0.3-0.8M NaCl pH7.5 low salt concn, obtain the elutriant containing high molecular recombinant protein, preferred low salt concn is 0.5M NaCl pH7.5; Under 1.0-2.0M NaCl pH7.5 high salt concentration, remove lower molecular weight recombinant protein, preferred 1.5M NaCl pH7.5 high salt concentration, the method can effectively separation of high molecular weight and lower molecular weight recombinant human kallidinogenase.
(4) hydrophobic chromatography column purification: adopt hydrophobic chromatography post, process the high molecular recombinant human kallidinogenase obtained in above-mentioned (3), utilize high low-molecular-weight difference, adopt the method for GE-AKTA system gradient elution, remove lower molecular weight recombinant human kallidinogenase and other impurity further.
Described drainage column comprises Butyl Sepharose 4Fast Flow, Octyl Sepharose 4Fast Flow, Phenyl Sepharose 6Fast Flow, Butyl-S Sepharose 6Fast Flow, Butyl Sepharose 4B, Octyl Sepharose CL-4B, Phenyl Sepharose CL-4B.Preferably, Phenyl Sepharose 6Fast Flow.
(5) low PH fire extinguishing virus: regulate PH to 3.8 by above-mentioned containing high molecular recombinant protein solution, 4 DEG C of constant temperature leave standstill 1 hour, realize the deactivation of virus.
(6) anion exchange chromatography: regulate the above-mentioned pH containing high molecular recombinant protein solution, make it electronegative, make target protein be attached to anion-exchange column, realizes the concentrated of high molecular recombinant protein.
Described anion-exchange column comprises Q Sepharose H.P, Q Sepharose F.F, Q Sepharose 4F.F, Q Sepharose XL, QAE Sephadex A-25, QAE Sephadex A-50, STREAMLINE Q XL.Preferably, QAE Sephadex A-25, QAE Sephadex A-50.
(7) molecular sieve gel column purification: by gel column purifying, makes high molecular recombinant human vascular relaxation fibroin be fully separated.
(8) above-mentioned gel column gained solution is passed through Depth Filtration film, remove virus residual.
Finally the high purity high molecular recombinant human vascular relaxation fibroin 0.22 μm of millipore filtration Sterile Filtration obtained will be separated.Described gel column comprises Sephadx G75, Sephadx G100, Superdex30prep grade, Superdex75prep grade, Superdex200prep grade, Superose 6prep grade, Superose 12prep grade, Sephacryl S-100HR, Sephacryl S-200HR, Sephacryl S-400HR, Sepharose 2B, Sepharose4B, Sepharose 6B.Preferably, Sephadex G75.
In the inventive method in step 1, the step building the expression vector of encoding recombinant human's kallidinogenase comprises: adopt artificial synthesis to obtain leading peptide and the mature protein gene (sequence No.1) of encoding human kallidinogenase, the expression vector (as pCMV-DHFR) being inserted into mammalian cell expression vector (as pCMV/ZEO) or improving, obtains containing people's kallidinogenase destination gene expression carrier pCMV-people's kallidinogenase-DHFR (Fig. 2).
Described mammalian cell expression vector can adopt commercially available but be not limited to, as: pCMV/ZEO, pIRES, pDR, pBK, pSPORT etc. can be used for the carrier that eukaryotic cell system is expressed.Those skilled in the art can select suitable expression vector according to host cell.Preferably, pCMV-DHFR (Fig. 2).
In the inventive method in step 2, recombinant human kallidinogenase step of stably express in mammalian host cell comprises: the expression vector containing people's vascular relaxation fibroin is transfected into mammalian host cell, the cell strain of screening stably express target protein.
Described cell transfecting method comprises electroporation transfection method (electroporation), calcium phosphate transfection, liposome transfection and Protoplast fusion, preferably, and electroporation transfection method.
Described mammalian host cell comprises CHO (Chinese Hamster Ovary, Chinese hamster ovary cell), HEK293, BHK, NS0 and Sp2/0 cell, preferably, and Chinese hamster ovary celI; More preferably, DHFR deficient CHO-suspension cell (DHFR-CHO) adapting to suspension growth in serum free medium has been tamed.
In the inventive method in step 3, the step of concentration cultivation Restruction people kallidinogenase comprises: the above-mentioned stable cell line screened is proceeded to cell response tank and carries out large scale culturing, particularly, by the optimization to cell culture condition, obtain the cell culture fluid of high expression level recombinant human kallidinogenase.Cell culture processes of the present invention can realize concentration cultivation, Quality and yield promotes and the glycosylation complexity of recombinant protein improves.
The optimization of described cell culture condition comprises cooling culture method, specifically, when cell density reaches 1 × 10
7individual/mL time, temperature is down to 33 DEG C by 37 DEG C, at such a temperature cultivate until express output no longer increase.The method can improve the activity level of expressing protein and the cumulative withdrawal of recombinant protein.
The optimization method of described cell culture condition also comprises and adds special additive in the medium, preferably, adds 100 μMs of Cu at basic medium T300
2+, feed and raise substratum and add 2mM ManNAc (N-ethanoyl-D-epichitosamine).The method can make the degree of glycosylation of recombinant human kallidinogenase increase, and the complexities such as glycosylation branch and side chain obviously increase.
The optimization method of described cell culture condition also comprises exclusive dynamic dissolved oxygen algorithm, dissolved oxygen is supplemented according to the different states of cell in the different steps of cultivating, preferably, the dissolved oxygen rate of more than 40% is kept at the cell cultures initial stage, 60%-70% dissolved oxygen rate is kept mid-term in cell cultures, in whole production process, keep dissolved oxygen rate linearly to increase curve, be conducive to increasing the speed that albumen enters golgi body, thus the degree of glycosylation of recombinant human kallidinogenase can be made obviously to increase.
In the inventive method in step 4, the purification step of high molecular recombinant human kallidinogenase of the present invention is: the present invention adopts specific purification by chromatography to prepare high molecular recombinant human kallidinogenase, this chromatography method overcomes the special purification process step (60 DEG C thermostatically heating 10 hours) that existing urine people from source kallidinogenase or recombinant human kallidinogenase all adopt due to it and easily causes the defect that its protein deamidation degree is higher, the high molecular recombinant human kallidinogenase stability obtained is better, and side effect obviously reduces.Specifically comprise following eight steps:
(1) pre-treatment before upper chromatography column: the above-mentioned nutrient solution containing recombinant human kallidinogenase is carried out centrifugal segregation cell debris, collecting cell supernatant liquor regulates pH and centrifugal segregation precipitation.
(2) anion exchange chromatography: with same anion chromatography post, use the Tris-HCl damping fluid of different N aCl concentration value, 0.2-0.4M NaCl prick post, 0.05-0.15M NaCl hanging column, successively makes recombinant human vascular relaxation fibroin prick post and hanging column.
Described anion-exchange column comprises: Q Sepharose H.P, Q Sepharose F.F, Q Sepharose 4F.F, Q Sepharose XL, QAE Sephadex A-25, QAE Sephadex A-50, STREAMLINE Q XL.Preferably, QAE Sephadex A-25, QAE Sephadex A-50.
(3) affinity column stepwise elution: adopt affinity column (Benzamidine Sepharose 4Fast Flow, GE) purifying, by the elution requirement of different salt concn, under 0.3-0.8M NaCl pH7.5 low salt concn, obtain the elutriant containing high molecular recombinant human vascular relaxation fibroin, preferred low salt concn is 0.5M NaCl pH7.5; Under 1.0-2.0M NaClpH7.5 high salt concentration, remove lower molecular weight recombinant protein, preferred 1.5M NaCl pH7.5 high salt concentration.The method can effectively separation of high molecular weight and lower molecular weight recombinant human kallidinogenase.
(4) hydrophobic chromatography column purification: adopt hydrophobic chromatography post, according to the hydrophobicity difference that high lower molecular weight recombinant human pipe is releived plain, the lower molecular weight recombinant human kallidinogenase in the high molecular recombinant human kallidinogenase that further removal above-mentioned (3) obtains and other impurity.
Described drainage column comprises Butyl Sepharose 4Fast Flow, Octyl Sepharose 4Fast Flow, Phenyl Sepharose 6Fast Flow, Butyl-S Sepharose 6Fast Flow, Butyl Sepharose 4B, Octyl Sepharose CL-4B, Phenyl Sepharose CL-4B.Preferably, Phenyl Sepharose 6Fast Flow.
(5) low PH fire extinguishing virus: regulate PH to 3.8 by above-mentioned containing high molecular recombinant protein solution, 4 DEG C of constant temperature leave standstill 1 hour, realize the deactivation of virus.
(6) anion exchange chromatography: regulate the above-mentioned pH containing high molecular recombinant protein solution, make it electronegative, make target protein be attached to anion-exchange column, realizes the concentrated of high molecular recombinant protein.
Described anion-exchange column comprises Q Sepharose H.P, Q Sepharose F.F, Q Sepharose 4F.F, Q Sepharose XL, QAE Sephadex A-25, QAE Sephadex A-50, STREAMLINE Q XL.Preferably, QAE Sephadex A-25, QAE Sephadex A-50.
(7) molecular sieve gel column purification: by gel column purifying, makes high molecular recombinant human vascular relaxation fibroin be fully separated.
(8) above-mentioned gel column gained solution is passed through Depth Filtration film, remove virus residual.
Finally the high purity high molecular recombinant human vascular relaxation fibroin 0.22 μm of millipore filtration Sterile Filtration obtained will be separated.
Described gel column comprises Sephadx G75, Sephadx G100, Superdex30prep grade, Superdex75prep grade, Superdex200prep grade, Superose 6prep grade, Superose 12prep grade, Sephacryl S-100HR, Sephacryl S-200HR, Sephacryl S-400HR, Sepharose 2B, Sepharose4B, Sepharose 6B.Preferably, Sephadex G75.
The high molecular recombinant human kallidinogenase prepared by the inventive method has following features:
(1) measured by SDS-PAGE electrophoresis method, high molecular recombinant human kallidinogenase molecular weight 43.0-49.0KDa of the present invention, being greater than people's UK molecular weight is 39.0-43.0KDa.
(2) high molecular recombinant human kallidinogenase of the present invention contains high-molecular-weight protein ratio more than 99%, and people's high-molecular-weight protein ratio in people's kallidinogenase and recombinant human kallidinogenase of urinating of conventional preparation is only 40%.
(3) its sugar-type complexity of 3 N-linked glycosylation sites that high molecular recombinant human kallidinogenase of the present invention contains is much higher than people's UK (reference table 2 glycosylation structure composition comparative result).
(4) the present invention makes the desamidization level in high molecular recombinant human kallidinogenase Asn84 site control be about 5%-15% by improving purifying process, be preferably 8.7%, far below the desamidization level (48.6%) of people's UK.
Another object of the present invention is the application of above-mentioned high molecular recombinant human kallidinogenase in treatment renal failure.
The present invention is owing to have employed specific Large-scale culture conditions and purification process, thus make the glycosylation of the high molecular recombinant human kallidinogenase obtained and desamidization degree and existing people's UK different, in clinical application, side effect obviously reduces, and especially comparatively relaxes blood pressure drops in body.
The advantage of high molecular recombinant human kallidinogenase of the present invention and preparation method thereof is:
Recombinant human kallidinogenase molecular weight of the present invention is 43.0-49.0KDa, and macromolecule protein ratio is much larger than people's UK; Containing 3 N-linked glycosylation sites, its sugar-type complexity is far above people's UK; The desamidization level in Asn84 site is about 5%-15%, is preferably 8.7%, far below people's UK (48.6%).High molecular recombinant human kallidinogenase of the present invention combines above multiple advantage, can significant prolongation Half-life in vivo and minimizing side effect.
1) host cell system has tamed DHFR deficient CHO-suspension cell (DHFR-CHO) adapting to suspension growth in serum free medium.This domestication suspend in adapting to Chinese hamster ovary celI can not only avoid before ordinary method express target gene cell and reduce from there being serum to adapt to consuming time and output to serum-free domestication, and its growing high density straight line in serum free medium can be made to amplify produce.
2) the dissolved oxygen scheme of adding some materials and optimization in cells produce engineering can make the level of glycosylation of recombinant human kallidinogenase increase.The method that this cooling is cultivated can improve the activity level of expressing protein and the cumulative withdrawal of recombinant protein.
3) high-molecular-weight protein purifying: four steps of conventional separation methods relatively, the present invention adds 3 steps in addition and optimizes affinity column and exclusive drainage column purification condition, is successfully separated and obtains highly purified high molecular recombinant human kallidinogenase.
4) purifying critical process controls protein deamidation level: easily cause its protein deamidation degree higher relative to the urine source people's kallidinogenase delivered or its special purifying process all adopted of common recombinant human kallidinogenase, affect stability and the homogeneity of albumen entirety, be exaggerated the shortcomings such as the short and side effect of its transformation period is large further, the present invention does not adopt the drastic conditions such as heating at whole purifying process, and the key parameter such as control PH completes whole flow process at normal temperatures all the time, final albumen deacylated tRNA amine level is effectively controlled.
Accompanying drawing explanation
Accompanying drawing highlights principle of the present invention, not necessarily proportional.
The nucleotide sequence (with SEQ ID:1) that Fig. 1 shows people's kallidinogenase (people's kallidinogenase) in expression vector pCMV-people kallidinogenase-DHFR and the aminoacid sequence (with SEQ ID:2) of deriving: containing signal peptide (1-18) and maturation protein (19-256).
Fig. 2 shows constructed gene mapping of expressing pCMV-people's kallidinogenase-DHFR eukaryon expression plasmid of recombinant protein people kallidinogenase.This expression plasmid total length 5820bp, containing 10 oligogene segments, comprises 1.CMV promotor; 2. target gene people kallidinogenase; 3.IRES element; 4. blasticidin resistance gene (zeocin); 5.BGH terminator; 6.SV40 promotor; 7.mDHFR screening-gene; 8.SV40 terminator; 9. ammonia benzyl mycin resistant gene (ampicillin); 10.pUC replicon;
Fig. 3 shows people's kallidinogenase maturation protein aminoacid sequence
Fig. 4 shows the growth of recombinant human kallidinogenase in 7L bio-reactor and expression
Fig. 5 shows molecular weight standards (M), people's UK (u people's kallidinogenase) and high molecular recombinant vascular of the present invention and to releive the SDS-PAGE protein electrophoresis collection of illustrative plates of element (recombinant human kallidinogenase).People's UK (Lane2) and high molecular recombinant vascular of the present invention element (Lane 3) molecular weight of releiving is about 39-43KDa and 43-49KDa respectively
Fig. 6 shows people's kallidinogenase single intravenous injection Drug-time curve (n=5) in rat body
Embodiment
Embodiment 1 builds the expression vector of encoding human kallidinogenase recombinant protein
Artificial synthesis is adopted to obtain leading peptide and the mature protein gene of encoding human kallidinogenase, total length 771bp (sequence 1 and Fig. 1), by this DNA fragmentation insertion vector as between the restriction enzyme site KpnI in pUC57, obtain plasmid pUC-people kallidinogenase.The accuracy of synthesis fragment is verified by DNA sequencing.
Employing artificial synthesis obtains the mouse DHFR gene and promotor and terminator fragment that contain restriction enzyme site EcoRI (5 ' end) and HindIII (3 ' end), be inserted in the corresponding restriction enzyme site of mammalian cell expression vector pCMV/ZEO (Invitrogen), obtain carrier pCMV-DHFR, DHFR contained by it and promotor and terminator sequence can be verified by DNA sequencing.
By the gene order of complete encoding human kallidinogenase recombinant protein that obtains after NheI and BamHI enzyme is cut, between the corresponding restriction enzyme site being inserted into mammalian cell expression vector.As shown in Figure 2, the final gene expression plasmid pCMV-people kallidinogenase-DHFR obtained.This plasmid contain can underwriter's kallidinogenase can stability and high efficiency express cytomegalovirus promoter CMV.Meanwhile, the selected marker thing also containing two types in this plasmid, wherein Zeocin (bleomycin) resistant gene is used to screening and transforms successful mammalian cell, and ammonia benzyl resistant gene is used for the colony screening of carrier in bacterium.In addition, the DHFR gene contained in this carrier can so that technician be when carrying out the mammalian cell clone screening stable high expression level, MTX (methotrexate) is utilized to come coamplification target protein gene people's kallidinogenase and DHFR gene, thus the high expression level of realize target gene people kallidinogenase.
The stably express of embodiment 2. recombinant human kallidinogenase in mammalian host cell
In order to express people's kallidinogenase recombinant protein, the expression vector pBudCE4.1-DHFR-people kallidinogenase of the encoding human kallidinogenase recombinant protein built is transfected into mammalian host cell line.Preferred host cell system is DHFR deficient CHO-cell (DHFR--CHO), and be more suitable for expression-secretion type albumen in order to host cell, and cell can reach more high-density, DHFR--CHO cell improves by we, improves one's methods and comprises transfected proteins enzyme and change cellular metabolic pathways.The preferred electroporation of cell transfecting method, also can use other method, comprises calcium phosphate cosedimentation, liposome transfection and Protoplast fusion.In electroporation, with GenePulser Electroporator (the Bio-Rad Laboratories being set to 250V electric field and 960 μ Fd electric capacity, Hercules, CA), add the linearizing plasmid DNA of 10 μ g PvuI in 2 ~ 5 × 107 cells in cuvette.
Transfection two days later, the growth medium made into by substratum containing 25 μ g/mL Zeocin carries out kind of a plate, cultivate after 10 days, carry out expressing the quantitative of recombinant human kallidinogenase to each hole in 96 orifice plates by the elisa assay method of anti-human kallidinogenase, filter out the higher clone of expression amount.In order to realize the high-caliber expression of recombinant human vascular relaxation fibroin, coamplification should be carried out with the DHFR gene by MTX Drug inhibition.With limiting dilution method kind 96 orifice plate, in the growth medium containing progressive concentration MTX, along with the amplification of DHFR gene, people's vascular relaxation plain gene of transfection also increases.The subclone that present method finally produces can grow in up to 10 μMs of MTX substratum.Do to analyze further to the secretion rate of subclonal cell line.Screening secretion level exceedes about 300 (preferably about 500) ng/10
6the clone of (namely 1,000,000) individual cell/24 hour, and make its suspension growth in serum free medium.
The cells produce of embodiment 3. recombinant human vascular relaxation fibroin
The cell strain that embodiment 2 obtains, has first adapted to suspension culture in shaking flask.People's kallidinogenase is glycosylated protein, the level of glycosylation of albumen is directly connected to its activity, and the side effect etc. after patent medicine, higher-quality people's kallidinogenase glycoprotein can be expressed to make people's kallidinogenase cell strain of structure, we carry out the optimization of substratum, by the simultaneous test at little shake-flask culture, add some substances and the level of glycosylation of recombinant human kallidinogenase is increased.Basic medium T300 adds 100 μMs of Cu
2+, feed and raise substratum and add 2mM ManNAc (N-ethanoyl-D-epichitosamine).After the shake-flask culture of cell is stable, in order to obtain more people's kallidinogenase recombinant protein, by cell amplification to q.s, carry out 7L bio-reactor batch cultivation.Bio-reactor setup parameter is: temperature 37 DEG C, pH6.90, dissolved oxygen 50%, rotating speed 100rpm.When cell density reaches 1 × 10
7individual/mL time, cool the temperature to 33 DEG C, at such a temperature cultivate until express output no longer increase, this cooling cultivate method can improve the activity level of expressing protein and the cumulative withdrawal of recombinant protein.It is 10.6mg/L that Fig. 4 shows its people's kallidinogenase cumulative withdrawal expressed.
The preparation of embodiment 4 high molecular recombinant human kallidinogenase
From the cell culture fluid of above-mentioned production, through following eight step purifying, the high molecular recombinant protein of purity >99% can be obtained, specifically comprise:
1) pre-treatment before upper chromatography column: collect the Chinese hamster ovary celI nutrient solution that 5L contains recombinant human kallidinogenase, centrifugal segregation cell debris, collects centrifugal supernatant; Centrifugal supernatant Millipore PELLICON20.5m210K film bag is carried out ultrafiltration and concentration, and adjust rearmounted 4 DEG C of pH to 4.0 to place 1 hour, centrifugal segregation precipitates, and collects supernatant and adjusts pH and conductance and Q column equilibration liquid phase same, entering next step column chromatography purification step.Before recombinant human kallidinogenase cultivation fluid column, purification yield is more than 90%.
2) Q Sepharose column chromatography: with 50mM Tris-HCl-0.3M NaCl pH7.5 damping fluid by Q post (Q SepharoseFast Flow, GE) fully balance, loading after regulating culture supernatant pH value consistent with Q column equilibration liquid, collects prick post liquid.Getting prick post liquid regulates salt concn again to go up QSepharose post after consistent with less salt balance liquid (50mM Tris-HCl-0.1M NaCl pH7.5), with using 50mM Tris-HCl 0.5M NaCl wash-out after the drip washing to baseline of less salt balance liquid, collect the active elution peak of recombinant human kallidinogenase.
3) affinity column chromatography (Benzamidine Sepharose): with the abundant balance columns of Benzamidine Sepharose 4Fast Flow balance liquid 50mM Tris-HCl-0.35M NaCl pH7.5 balance liquid; Get active collection liquid upper prop, with the drip washing of 50mMTris-HCl-0.5M NaCl pH7.5 damping fluid; Use 50mM Tris-HCl-0.7M NaCl pH7.5 and 50mMTris-HCl-1.5M NaCl pH7.5 wash-out respectively, collect the elutriant of pbz polymer amount recombinant human kallidinogenase and lower molecular weight recombinant human kallidinogenase respectively.
4) hydrophobic chromatography (Phenyl Sepharose): with 50mM Tris-HCl-0.9M ammonium sulfate, pH7.0 fully balances drainage column; Get affinity chromatography activity and collect liquid upper prop, collection penetrates liquid containing recombinant protein.
5) above-mentioned collection liquid is regulated PH to 3.8,4 DEG C of constant temperature preserve 1 hour.
6) Q Sepharose post concentrates: with 50mM Tris-HCl-0.15M NaCl pH7.5 balance liquid by Q post (QSepharose Fast Flow, GE) fully balance, the above-mentioned liquid that penetrates is regulated to regulate upper prop after pH and conductance, by the buffer solution elution of 50mMTris-HCl-0.35M NaCl pH7.5, collect recombinant human kallidinogenase Peak Activity.
7) molecular sieve gel column chromatography: moving phase is 20mM PB, pH7.0, flow velocity 1ml/min, fully loading after balance SephadexG75 post, collects recombinant human kallidinogenase Peak Activity.
8) by the Depth Filtration film of gained solution by 33 square centimeters, virus is removed residual, with 0.22 μm of millipore filtration Sterile Filtration, therefrom sample thief A.
The purification process of the present embodiment 4 can effectively isolate high molecular recombinant protein, as shown in Figure 5, through SDS-PAGE electrophoretic analysis, obtains the high molecular recombinant human kallidinogenase of purity >99%.Measure through N terminal amino acid sequence, result shows that high molecular recombinant human vascular relaxation prime sequences is identical with Fig. 3 with sequence 3.
The structural analysis of embodiment 5 high molecular recombinant human kallidinogenase
N-end 15 amino-acid residues measure: adopt Edman edman degradation Edman, embodiment 4 high molecular recombinant human kallidinogenase has been carried out to the sequencing of N-end 15 amino-acid residues.Sequence is: Ile-Val-Gly-Gly-Trp-Glu-Cys-Glu-Gln-His-Ser-Gln-Pro-Trp-Gln is identical with reported in literature.
Amino acid composition analysis: correct amount sample thief enters to be hydrolyzed in pipe, adds 6mol/L hydrochloric acid, and in 110 DEG C of hydrolysis 24 hours, cooling constant volume, filter, the hydrochloric acid that removed by evaporation is excessive, used 0.02mol/L constant volume, measure with amino acidanalyser.
Measurement result is in table 1, basically identical with reported in literature value, the primary structure of high molecular recombinant human kallidinogenase is the strand containing 238 amino-acid residues, there are five pairs of disulfide linkage at Cys7-Cys150, Cys 26-Cys42, Cys129-Cys196, Cys161-Cys175 and Cys186-Cys211 respectively, there is glycosylation at Asn78, Asn84 and Asn141 place.
Table 1 amino acid composition analysis result
Glycosylation structure compares:
The qualitative and quantitative analysis that glycosylation modified peptide section, high precision LC-MS mass spectrometric detection and MASS SPECTRAL DATA ANALYSIS software PepfinderTM carry out glycopeptide level is obtained by protease hydrolyzed protein.
Result shows, containing 3 N-Link glycosylation sites: Asn78, Asn84 and Asn141, all far above people's UK (commercialized product) in the glycosylation complexity in 3 sites, wherein the complicated N sugar side chain people UK of three side chains and four side chains does not almost have (table 2), and high molecular recombinant human kallidinogenase of the present invention obtains the degree of depth in this respect and strengthens, this also exactly can confirm the reason that the transformation period extends greatly.
Table 2 glycosylation structure composition comparative result
The mensuration of embodiment 6 recombinant human kallidinogenase desamidization level
Sample A: high molecular recombinant human kallidinogenase prepared by embodiment 4 method
Sample B: people's UK (commercialized product)
Desamidization measuring method: obtain the qualitative and quantitative analysis that glycosylation modified peptide section, high precision LC-MS mass spectrometric detection and MASS SPECTRAL DATA ANALYSIS software PepfinderTM carry out glycopeptide level by protease hydrolyzed protein.
Experimental result:
As shown in table 3, be respectively 8.69% and 48.64% through LC-MS mass spectroscopy high molecular recombinant human kallidinogenase and people's UK in the desamidization level in 84 sites, namely people's UK desamidization level is more than 5 times of high molecular recombinant human kallidinogenase.
The horizontal analysis of table 3 desamidization
By etc. weight 1mg high molecular recombinant human kallidinogenase and people's UK be dissolved in 10ml physiological saline respectively, be placed in 37 DEG C of constant-temperature enclosed placements (simulation human body temperature and environment), sample specific activity in detection Mice Body week about, found that in people's UK body, specific activity is reduced to 68% the 9th week time, and high molecular recombinant human kallidinogenase still maintains more than 96% (as following table 4).
The stability of table 4 recombinant human kallidinogenase and people's UK
| Classification | 0th week | 1st week | 2nd week | 3rd week | 4th week | 5th week | 6th week | 7th week | 8th week | 9th week |
| High molecular recombinant human kallidinogenase | 100％ | 103..50％ | 101..20％ | 106..80％ | 99..52％ | 98..21％ | 96..57％ | 98..25％ | 95..11％ | 96..01％ |
| People's UK | 100％ | 105..24％ | 100..89％ | 98..85％ | 102..00％ | 97..79％ | 96..68％ | 90..85％ | 72..35％ | 68..52％ |
More than test the production technique showing to be improved by the present invention, the desamidization level of product significantly reduces, and this is conducive to increasing albumen homogeneity and stability, reduces the potential side effect of product; And commercially available prod is owing to have employed the technique (60 DEG C of long-time heating, 10 hours), its desamidization level has exceeded 5 times than present invention process, easily there is reaction such as hydrolysis grade in vivo under environment and cause biological activity to be lost in albumen, this is not only unfavorable for that albumen itself keeps stable, and affecting the homogeneity of product, the risk had side effects promotes greatly.
Embodiment 7 recombinant human vascular relaxation element external activity and other physical and chemical property determinings
Sample A: high molecular recombinant human kallidinogenase prepared by embodiment 4 method
Sample B: people's UK (commercialized product)
Activity determination method: by alcoholdehydrogenase coupling method, adopt substrate A c-Phe-Arg-OEt (reference: Geiger, R., and Fritz, H. (1981) Methods Enzymol.80,466-492.) measure the enzymic activity of above-mentioned sample.Result shows, high molecular recombinant human kallidinogenase (sample A) specific activity is 1580U/mg albumen, higher than people's UK (specific activity is 1010U/mg albumen).
The plasma half-life of embodiment 8 recombinant human kallidinogenase measures
Get SPF level male SD rat, 2 groups are divided into by random packet principle, be respectively: the embodiment of the present invention 4 high molecular recombinant human kallidinogenase (1.0PANU/Kg), people's UK group (1.0PANU/Kg), often organize 5 animals, by the administration of tail single intravenous injection.Respectively at 2min, 5min, 15min, 30min, 45min, 60min, 120min, 360min, 720min after administration, eye socket blood sampling 0.5ml, and use heparin sodium anti-freezing.At 4 DEG C, blood sample is got blood plasma with 4000rpm centrifugation, and to adopt in embodiment 6 external activity detection method to detect blood plasma medium vessels to releive cellulose content.Take time as transverse axis, vascular relaxation cellulose content is the longitudinal axis, makes Drug-time curve as Fig. 6.
The plasma half-life of two groups of treated animals is calculated by PKsolver 2.0 pharmacokinetics software for calculation, result all meets two-compartment model, wherein the α phase of recombinant human kallidinogenase and β phase transformation period are respectively 8.37 ± 2.75min and 396.34 ± 81.03min, and α phase and the β phase transformation period of people's UK are respectively 4.69 ± 0.68min and 144.21 ± 33.45min.Result shows, counterpart's UK plasma half-life that high molecular recombinant vascular is releived plain nearly 2 times (table 5) increases.
Table 5 kallidinogenase in rat body single intravenous injection medicine for parameter
Embodiment 9 recombinant human kallidinogenase is on the impact of blood pressure
Get healthy regular grade beagle dog, body weight 10-13kg, male and female all have, and are divided into saline control group (NS group), the embodiment of the present invention 4 high molecular recombinant human kallidinogenase group (15 × 10 at random
-3pANU/Kg), people's UK group (15 × 10
-3pANU/Kg), often 6 animals are organized.3% vetanarcol (35mg/kg) intravenous injection row general anesthesia, back of the body position is fixed.Tracheostomize, inserts trachea cannula, keeps smooth breathing.Side femoral arteriography the Measure blood pressure that is connected with pressure transducer.Be separated left common carotid, intubate to left ventricle connects transverter and surveys left indoor pressure.Standard I I helical pitch is led recording ecg.Isolate right external jugular vein and threading, to be on the waiting list blood.In left side fourth, fifth intercostal incision skin, be separated intercostal muscle.Start breathing apparatus's (16 times/min), remove this two roots bone, strut chest incision with machine for chest-opening, expose heart, make pericardium cradle.Be separated left anterior descending coronary artery trunk for line, place TANSONIC laser Doppler flowmetry probe dynamic monitoring coronary flow.Surgical injury is complete, after all observation indexs are stable, record normal index, before administration is recorded in then intravenous drip administration (persistent instillation 30min) respectively and after administration when 5min, 10min, 20min, 30min, 45min, 60min, 90min, 120min: systolic pressure (SAP), diastolic pressure (DAP), mean arterial blood pressure (MAP).
Result: each group different time points arterial tension values is as table 6, table 7 and table 8.Result is visible, administration group all can make blood pressure obviously decline (compare or compare with control group P with before administration and all have < 0.05), 20min step-down is about the most obvious in administration, wherein people's UK blood pressure reduces 26%, and high molecular recombinant human kallidinogenase of the present invention only reduces by 16%.Illustrate that high molecular recombinant human kallidinogenase is the same with people's UK, there is the pharmacologically active reduced blood pressure, but due to the prolongation of transformation period, under Isodose, the reducing effect counterpart UK of high molecular recombinant human kallidinogenase to blood pressure more relaxes, and the side effect brought to patient is less.
Table 6 kallidinogenase is on the impact of normal dogs systolic arterial pressure (SAP)
T-test: compare with before administration, * are P<0.05..
Table 7 kallidinogenase is on the impact of normal dogs auterial diastole pressure (DAP)
T-test: compare with before administration, * are P<0.05.
Table 8 kallidinogenase is on the impact of normal dogs artery mean pressure (MAP)
T-test: compare with before administration, * are P<0.05.
Embodiment 10 recombinant human kallidinogenase is studied the therapeutic action of acute renal failure rat
1) to the therapeutic action of gentamicin induced Acute renal failure
SD rat is divided at random Normal group (0.9% physiological saline), model group (0.9% physiological saline), high molecular recombinant human kallidinogenase group (3.75U/Kg), people's UK group (3.75U/Kg), except Normal group penetrates normal saline, all the other respectively organize equal abdominal injection gentamicin 140mg/kg, continuous 7 days.After modeling success, be divided into above 7 groups at random, except normal, all the other are respectively organized all every abdominal injection gentamicin 100mg/kg on the one, continuous 3 times, Normal group injection normal saline.Each group of according to dosage tail vein injection administration, high molecular recombinant human kallidinogenase group is administration in the 1st, 3,5,7 day after modeling, and other respectively organize equal successive administration 7 days.In modeling the 7th day, carry out pharmacological agent 7 days, after last administration, 24h gets blood respectively, and application automatic clinical chemistry analyzer measures serum urea nitrogen (UREA), creatinine (CR), serum cystatin C (Cys-C) respectively.
The results are shown in Table 9, data show: high molecular recombinant human kallidinogenase and people's UK all obviously can reduce the content (comparing p < 0.05 or p < 0.01 with model group) of creatinine in blood, blood urea nitrogen, serum cystatin C (Cys-C).In a word, high molecular recombinant human kallidinogenase has obvious therapeutic action to rat injection gentamicin induced Acute renal failure.
Table 9 is on the impact of serum UREA, CR and CYS-C content
Note: model group compares with sham-operation:
△p < 0.05,
△ △the each administration group of p < 0.01 compares with model group:
*p<0.05,
*p<0.01
2) to the effect of rat kidney ischemia-reperfusion induced Acute renal failure
SD rat is divided at random Normal group (0.9% physiological saline), model group (0.9% physiological saline), high molecular recombinant human kallidinogenase group (3.75U/Kg), people's UK group (3.75U/Kg).
Modeling method: with 3% vetanarcol abdominal injection (0.15ml/100g body weight) anesthetized rat, take the stringer otch being about row about long 1.5cm in 0.5cm place through back of the body bilateral arcus costarum lower edge apart from backbone, blunt separation also exposes the right side kidney base of a fruit, ligation also excises Rat Right kidney, the left side kidney base of a fruit is closed with non-invasive bulldog clamp folder, left side Renal artery ischemic kidney color is first lost color by bright red, then garnet is transferred to, after 45min, pine folder recovers perfusion, kidney color becomes bright red again, determine successively close abdomen after kidney recovers blood flow and sew up the incision, set up renal ischemia/reperfusion injury model, postoperative rat freely ingests and drinks water.Sham-operated control group is at back of the body bilateral otch, and blunt separation after exposing bilateral renal also exposes the Bilateral Renal base of a fruit, and cover the gauze being soaked with physiological saline, successively close abdomen after removing gauze after 45min, sew up the incision, postoperative rat freely ingests and drinks water.
After modeling success, respectively organize according to dosage tail vein injection administration, high molecular recombinant human kallidinogenase group is administration in the 1st, 3,5,7 day after modeling, and other respectively organize equal successive administration 7 days.Before experiment, after experiment, the 2nd day, the 4th day, the 7th day large rathole socket of the eye is got blood system and is not detected creatinine in serum (CR), blood urea nitrogen (UREAc), serum cystatin C (Cys-C).
The results are shown in Table 10 and table 11, data show:
Impact on serum UREAc content: compared with sham operated rats, after experiment, model group serum UREAc significantly raises (p < 0.01); Compared with model group, latter 2nd day of experiment, high molecular recombinant human kallidinogenase group serum UREAc content obviously reduces (p < 0.01); Latter 4th day of experiment, high molecular recombinant human kallidinogenase group and people's kallidinogenase group serum UREAc content reduce and have statistical significance (p < 0.05), latter 7th day of experiment, heavy high molecular recombinant human kallidinogenase group and people's kallidinogenase group serum UREAc content reduce and have statistical significance (p < 0.05).
Impact on change of serum C R content: compared with sham operated rats, after experiment, model group change of serum C R significantly raises (p < 0.01); Latter 2nd day of experiment, compared with model group, high molecular recombinant human kallidinogenase group change of serum C R content reduces and has statistical significance (p < 0.05); Latter 4th day and the 7th day of experiment, high molecular recombinant human kallidinogenase group group and everybody kallidinogenase group change of serum C R content all reduce and have statistical significance (p < 0.05).
The change (x ± s, n=12) of table 10 renal ischemia/reperfusion injury each time point serum UREAc
Note: model group compares with sham operated rats:
△p < 0.05,
△ △p < 0.01 administration group compares with model group:
*p < 0.05,
*p < 0.01
The change (x ± s, n=12) of each time point change of serum C R of table 11 renal ischemia/reperfusion injury
Note: model group compares with sham operated rats:
△p < 0.05,
△ △p < 0.01 administration group compares with model group:
*p < 0.05,
*p < 0.01
In a word, high molecular recombinant human kallidinogenase has obvious therapeutic action to rat kidney ischemia-reperfusion induced Acute renal failure.And, because the transformation period is more than one times of people's UK, make it more lasting to the curative effect of MCAO rat model under same dosage, only need be administered once within the same time and just can reach the effect of people's UK administration 2 times.Can calculate thus, in the clinical application in high molecular recombinant human kallidinogenase future, because its administration number of times is few, patient's convenient drug administration, compliance is high, has good DEVELOPMENT PROSPECT.
Claims (8)
1. a high molecular recombinant human kallidinogenase, is characterized in that, forms a single chain protein by 238 amino-acid residues, and its aminoacid sequence is that sequence 3, N-end and C-terminal amino acid residue are respectively Isoleucine and Serine; Its molecular weight of SDS-PAGE cataphoretic determination is 43-49KDa; Containing 5 pairs of S-S keys, be respectively Cys7-Cys150, Cys26-Cys42, Cys129-Cys196, Cysl61-Cys175 and Cys186-Cys211.
2. high molecular recombinant human kallidinogenase according to claim 1, it is characterized in that, this recombinant human kallidinogenase is containing 3 N-Link glycosylation binding sites, lay respectively at Asn78, Asn84 and Asn141, in molecule, the desamidization level in Asn84 site is about 5%-15%, be preferably 8.7%, iso-electric point is about 4.0.
3., according to a kind of preparation method of high molecular recombinant human kallidinogenase of claim 1, its step comprises:
1) expression vector of encoding recombinant human's kallidinogenase is built:
Artificial synthesis is adopted to obtain the leading peptide of encoding human kallidinogenase and the mature protein gene of sequence No.1, the expression vector (as pCMV-DHFR) being inserted into mammalian cell expression vector (as pCMV/ZEO) or improving, obtains containing people's kallidinogenase destination gene expression carrier pCMV-people kallidinogenase-DHFR;
2) stably express of recombinant human kallidinogenase in mammalian host cell:
Expression vector containing people's vascular relaxation fibroin is transfected into mammalian host cell, the cell strain of screening stably express target protein;
3) concentration cultivation Restruction people kallidinogenase:
The above-mentioned stable cell line screened is proceeded to cell response tank and carries out large scale culturing, when cell density reaches 1 × 10
7individual/mL time, temperature is down to 33 DEG C by 37 DEG C, at such a temperature cultivate until express output no longer increase;
4) purifying of high molecular recombinant human kallidinogenase:
(1) pre-treatment before upper chromatography column: the above-mentioned nutrient solution containing recombinant human kallidinogenase is carried out centrifugal segregation cell debris, collecting cell supernatant liquor regulates pH and centrifugal segregation precipitation.
(2) anion exchange chromatography: with same anion chromatography post, use different salt concn value Tris-HCl+NaCl damping fluid, 0.2-0.4M NaCl prick post, 0.05-0.15M NaCl hanging column, successively makes recombinant human vascular relaxation fibroin prick post and hanging column.
Described anion-exchange column comprises: Q Sepharose H.P, Q Sepharose F.F, Q Sepharose 4F.F, Q Sepharose XL, QAE Sephadex A-25, QAE Sephadex A-50, STREAMLINE Q XL.Preferably, QAE Sephadex A-25, QAE Sephadex A-50.
(3) affinity column stepwise elution: adopt affinity column (Benzamidine Sepharose 4Fast Flow, GE) purifying, by the elution requirement of different salt concn, under 0.3-0.8M NaCl pH7.5 low salt concn, obtain the elutriant containing high molecular recombinant protein, preferred low salt concn is 0.5M NaCl pH7.5; Under 1.0-2.0M NaCl pH7.5 high salt concentration, remove lower molecular weight recombinant protein, preferred 1.5M NaCl pH7.5 high salt concentration, the method can effectively separation of high molecular weight and lower molecular weight recombinant human kallidinogenase.
(4) hydrophobic chromatography column purification: adopt hydrophobic chromatography post, process the high molecular recombinant human kallidinogenase obtained in above-mentioned (3), utilize high low-molecular-weight difference, adopt the method for GE-AKTA system gradient elution, remove lower molecular weight recombinant human kallidinogenase and other impurity further.
Described drainage column comprises Butyl Sepharose 4Fast Flow, Octyl Sepharose 4Fast Flow, Phenyl Sepharose 6Fast Flow, Butyl-S Sepharose 6Fast Flow, Butyl Sepharose 4B, Octyl Sepharose CL-4B, Phenyl Sepharose CL-4B.Preferably, Phenyl Sepharose 6Fast Flow.
(5) low PH fire extinguishing virus: regulate PH to 3.8 by above-mentioned containing high molecular recombinant protein solution, 4 DEG C of constant temperature leave standstill 1 hour, realize the deactivation of virus.
(6) anion exchange chromatography: regulate the above-mentioned pH containing high molecular recombinant protein solution, make it electronegative, make target protein be attached to anion-exchange column, realizes the concentrated of high molecular recombinant protein.
Described anion-exchange column comprises Q Sepharose H.P, Q Sepharose F.F, Q Sepharose 4F.F, Q Sepharose XL, QAE Sephadex A-25, QAE Sephadex A-50, STREAMLINE Q XL.Preferably, QAE Sephadex A-25, QAE Sephadex A-50.
(7) molecular sieve gel column purification: by gel column purifying, makes high molecular recombinant human vascular relaxation fibroin be fully separated.
(8) above-mentioned gel column gained solution is passed through Depth Filtration film, remove virus residual.
Finally the high purity high molecular recombinant human vascular relaxation fibroin 0.22 μm of millipore filtration Sterile Filtration obtained will be separated.Described gel column comprises Sephadx G75, Sephadx G100, Superdex30prep grade, Superdex75prepgrade, Superdex200prep grade, Superose 6prep grade, Superose 12prep grade, SephacrylS-100HR, Sephacryl S-200HR, Sephacryl S-400HR, Sepharose 2B, Sepharose 4B, Sepharose6B.Preferably, Sephadex G75.
4. the preparation method of high molecular recombinant human kallidinogenase according to claim 3, wherein step 1) described in expression vector be pCMV/ZEO, pIRES, pDR, pBK, pSPORT or pCMV-DHFR, preferably, pCMV-DHFR.
5. the preparation method of high molecular recombinant human kallidinogenase according to claim 3, wherein step 2) described in cell transfecting method comprise electroporation transfection method, calcium phosphate transfection, liposome transfection and Protoplast fusion, preferably, electroporation transfection method; Described mammalian host cell comprises CHO (Chinese Hamster Ovary, Chinese hamster ovary cell), HEK293, BHK, NS0 and Sp2/0 cell, preferably, and Chinese hamster ovary celI; More preferably, DHFR deficient CHO-suspension cell (DHFR-CHO).
6. the preparation method of high molecular recombinant human kallidinogenase according to claim 3, wherein step 3) in also comprise and add additive in the medium, preferably, add 100 μMs of Cu at basic medium
2+, feed and raise substratum and add 2mM ManNAc (N-ethanoyl-D-epichitosamine).
7. the application of high molecular recombinant human kallidinogenase in preparation treatment renal failure medicine of claim 1-2.
8. according to the high molecular recombinant human kallidinogenase that the preparation method of claim 3-6 obtains.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510159607.9A CN104861057B (en) | 2015-04-03 | 2015-04-03 | Recombinant human kallidinogenase and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510159607.9A CN104861057B (en) | 2015-04-03 | 2015-04-03 | Recombinant human kallidinogenase and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104861057A true CN104861057A (en) | 2015-08-26 |
| CN104861057B CN104861057B (en) | 2016-04-27 |
Family
ID=53907283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510159607.9A Active CN104861057B (en) | 2015-04-03 | 2015-04-03 | Recombinant human kallidinogenase and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104861057B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109678969A (en) * | 2018-12-29 | 2019-04-26 | 北京东方百泰生物科技有限公司 | A kind of purification process of CTLA4-Ig fusion protein |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101134953A (en) * | 2007-07-02 | 2008-03-05 | 广东天普生化医药股份有限公司 | Recombinant human pancreas kininogenase |
| CN101134105A (en) * | 2007-07-02 | 2008-03-05 | 广东天普生化医药股份有限公司 | Pharmaceutical composition containing recombination human pancreatic kininogenase for treating and/or preventing cerebral infarction |
| CN101879308A (en) * | 2010-06-13 | 2010-11-10 | 广东天普生化医药股份有限公司 | Application of human urinary kallidinogenase in preparing medicine for treating acute renal failureacute renal failure |
| CN104830822A (en) * | 2015-04-03 | 2015-08-12 | 广州优联康医药科技有限公司 | Recombinant human kallikrein |
-
2015
- 2015-04-03 CN CN201510159607.9A patent/CN104861057B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101134953A (en) * | 2007-07-02 | 2008-03-05 | 广东天普生化医药股份有限公司 | Recombinant human pancreas kininogenase |
| CN101134105A (en) * | 2007-07-02 | 2008-03-05 | 广东天普生化医药股份有限公司 | Pharmaceutical composition containing recombination human pancreatic kininogenase for treating and/or preventing cerebral infarction |
| CN101879308A (en) * | 2010-06-13 | 2010-11-10 | 广东天普生化医药股份有限公司 | Application of human urinary kallidinogenase in preparing medicine for treating acute renal failureacute renal failure |
| CN104830822A (en) * | 2015-04-03 | 2015-08-12 | 广州优联康医药科技有限公司 | Recombinant human kallikrein |
Non-Patent Citations (1)
| Title |
|---|
| GIORGIO RASPI: "kallikrein-like proteinases: purification and determination by chromatographic and electrophoretic methods", 《JOURNAL OF CHROMATOGRAPHY B》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109678969A (en) * | 2018-12-29 | 2019-04-26 | 北京东方百泰生物科技有限公司 | A kind of purification process of CTLA4-Ig fusion protein |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104861057B (en) | 2016-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104830822A (en) | Recombinant human kallikrein | |
| CN103497246B (en) | The Factor VlII molecule puted together | |
| CN110204608A (en) | One primary yeast fermentation small molecule recombination fibronectin peptide and its preparation method and application | |
| JP3394040B2 (en) | Compositions and methods of synthesis and use of natriuretic protein receptor B | |
| CN101134105B (en) | Pharmaceutical composition containing recombination human pancreatic kininogenase for treating and/or preventing cerebral infarction | |
| CN103539860A (en) | Long-acting recombinant human follicle-stimulating hormone-Fc fusion protein (hFSH-Fc) | |
| CN109053893A (en) | A kind of anti-D-dimer antibody and preparation method thereof | |
| EP3604343A1 (en) | Fusion protein, preparation method therefor and use thereof | |
| CN114478806B (en) | Chimeric receptor for improving killing activity of immune cells and application thereof | |
| CN102295695B (en) | Recombinant human follicle stimulating hormone and preparation thereof | |
| CN109153709A (en) | Nerve growth factor mutant | |
| CN103539861B (en) | Long-acting recombinant human follicle-stimulating hormone-Fc fusion protein (hFSH-Fc) | |
| CN104342420B (en) | A kind of recombinant long-acting people hyaluronidase, its encoding gene, production method and application | |
| CN104861057B (en) | Recombinant human kallidinogenase and application thereof | |
| CN105367664A (en) | Preparation method for dual-functional fusion protein capable of activating GLP-1 receptor and Amylin receptor and application of fusion protein | |
| CN103897064A (en) | Long-acting recombinant human chorionic gonadotrophin-Fc fusion protein | |
| CN101134953B (en) | Recombinant human pancreas kininogenase | |
| CN105601735A (en) | Intravenously injected cytomegalovirus human immune globulin and preparation method thereof | |
| CN108558997A (en) | A kind of application of recombination fusion protein TIGIT-Fc and its resisting transplant rejection reaction | |
| CN108410893A (en) | A kind of tumour cell specific response expression vector started by NF- κ B and its expression product and application | |
| CN103923898A (en) | PEG (polyethylene glycol) modified recombinant arginine deiminase (ADI) as well as preparation method and application thereof | |
| CN105218683B (en) | A kind of Tat PTD-Endostatin-RGD recombinant protein and the preparation method and application thereof | |
| CN101481692B (en) | Non-blood serum preparation of recombinant human blood coagulation factor IX | |
| CN108218978A (en) | A kind of recombinant interleukin 18 and preparation method and application | |
| CN101979576A (en) | Method for preparing vasonatrin peptide (VNP) by genetic engineering recombination technology |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20161111 Address after: 510703, No. 9, Tung Shing Street, Guangzhou economic and Technological Development Zone, Guangdong, China Patentee after: Guangzhou best Biotechnology Co., Ltd. Address before: 510663 Guangdong city of Guangzhou province Luogang District Science City on Guangzhou Road No. 3 international business incubator F Building 9 floor Patentee before: Guangzhou Youliankang Pharmaceutical Technology Co., Ltd. |